S-100 protein in methyl- and ethylnitrosourea induced tumors of the rat nervous system

Malignant renal schwannoma in a cat

A nine-year-old male European shorthair cat with rapidly enlarging mass at the left kidney doubted to be malignant was presented. The purpose of this study is to present the clinical, radiological and pathological findings of a primary renal tumor in the cat. Grossly, the mass mostly encapsulated the kidney. Histologically, excisional biopsy showed worrying histological features. A sarcoma-like tumor composed mainly of neoplastic spindle-shaped cells. Neoplastic nodules of aggregations of fusiform cells arranged in multidirectional bundles. Immunohistochemically, several immunohistochemical satins (melan-A, S-100, vimentin, actin, desmin, cytokeratin, neurofilament, melan-A, NSE, synaptophysin, chromogranin, Glial Fibrillary Acidic Protein GFAP, Collagen IV and CD99) were used to differentially diagnose the mass. The stained neoplastic sections positively tested to S-100, but negative to the other aforementioned immunohistochemical stains. Immunohistochemistry with S-100 antibody staining showed an unusually strong positive reaction throughout the tumor cells. Based on our comparative diagnosis relative to other tumors, in addition to the progressive clinical signs, histopathological and immunohistochemical results, this case was presumptively diagnosis as a malignant schwannoma. According to our investigation of the relevant literature, this study of malignant renal Schwannoma (malignant peripheral nerve sheath tumor) is a highly rare case not previously characterized in a cat.

Immunochemistry of ethylnitrosourea-induced rat neurinomas, the RN6 neurinoma cell line and their transplantation tumors

The expression of glial fibrillary acidic protein (GFAP), vimentin, S-100 protein (S-100), HNK-1, myelin basic protein (MBP) and fibronectin was investigated immunohistochemically in 51 ethylnitrosourea (ENU)-induced neurinomas of the rat. Additionally, 90 transplantation tumors derived from ENU-induced neurinomas and the RN6 rat neurinoma cell clone were studied. Vimentin immunoreactivity was shown in 50/51 primary neurinomas and 60/90 transplantation tumors. In contrast, GFAP was expressed in only 23/51 primary tumors and in 5/90 transplantation tumors. In the RN6 neurinoma clone, vimentin and GFAP could be demonstrated both in vivo and in vitro. GFAP expression varied depending on the tumor localization, i.e., tumors of distal portions of peripheral nerves were more frequently GFAP positive than tumors of the spinal roots or of cranial nerves. The same tendency was observed for S-100. In the series of transplantation tumors S-100 and GFAP immunoreactivity decreased with increasing numbers of transplantation passages. Only individual cells in 5 primary tumors were HNK-1 positive and no MBP-immunoreactive cells were observed. Our results demonstrate that the expression of differentiation antigens in ENU-induced experimental neurinomas parallels the results reported for human neurinomas.

A retrospective survey of endocardial proliferative lesions in rats

Sixty, proliferative, endocardial lesions were diagnosed in 19,304 rats, for an overall incidence of 0.3%. This population consisted of 10,127 Fischer 344, 8,737 Wistar, 200 Sprague-Dawley, and 240 Long Evans rats from chronic/oncogenicity studies reported at Lilly Research Laboratories from 1976 to 1988. Of the 60 proliferative lesions, 44 were classified as endocardial hyperplasia, 15 as endocardial schwannomas, and one as an endocardial sarcoma for prevalence rates of 0.2%, 0.08%, and 0.005%, respectively. Affected rats ranged in age from 42 to 110 weeks. There were no sex or treatment-related differences in the prevalence of the rat endocardial proliferative lesions. A review of endocardial lesions in 18 of 233 Wistar rats treated with carbamate derivatives revealed endocardial hyperplasia in 12 rats, schwannomas in five rats, and a sarcoma in one rat. One of the 12 rats with endocardial hyperplasia also had an intramural schwannoma. Of 200 Wistar rats given N-nitroso-N-methylurea, two had endocardial hyperplasia, and one had an endocardial schwannoma. Morphologic features were similar in either spontaneous or treatment-associated hyperplasia or neoplasia of the rat endocardium. Probable Schwann cell origin of the endocardial proliferative lesions was indicated by positive immunohistochemical staining for S-100 antigen in 10/12 spontaneous and 11/14 carcinogen-associated endocardial hyperplastic lesions. Further, 15/16 spontaneous and 6/7 carcinogen-associated neoplasms were immunoreactive to S-100. No tumor metastasis was recorded in either the spontaneously affected or carcinogen-treated rats.

Immunohistochemical investigations in experimentally induced tumors of the nervous system

35 tumors of brain, spinal cord and cranial and peripheral nerves were induced with ENU (ethyl-nitrosourea) in the offspring of treated BD-IX pregnant rats. 36 tumors--35 of the nervous system, one nephroblastoma--were observed in 14 rats. With these results, the number of experimental nervous system tumors of the own collection induced in BD-IX rats and classified next to the rules of human neurooncology, amounts to 2,216. All 35 tumors of the nervous system were treated by a panel of immunohistochemical reactions comprising antibodies against cytoskeleton intermediary filaments such as GFAP (glial fibrillary acid protein), neurofilament proteins, vimentin and cytokeratins and some nervous system antigens such as NSE (neuron specific enolase), MBP (myelin basic protein) and S-100 protein. In central tumors, considered to be malignant gliomas, focal reactivity against vimentin and GFAP was found. Expression of other tested markers was weak or absent. In neurinoma of trigeminal and peripheral nerves, reactivity to S-100 antigen was lacking, whilst there was strong reaction to the vimentin antigen.

Morphologic and immunohistochemical features of two spontaneous peripheral nerve tumors in Wistar rats

Morphologic features and S-100 protein immunoreactivity of a benign and malignant peripheral nerve sheath tumor were studied in two Wistar rats. Neoplasms that developed in untreated control rats from tumor bioassays were S-100 protein positive and had similar histopathologic features. Each peripheral nerve sheath tumor was encapsulated and composed of spindle cells arranged around small thin-walled blood vessels. Palisaded tumor cells were in the benign peripheral nerve sheath tumor while cells of the malignant peripheral nerve sheath tumor had cellular atypia and moderate numbers of mitoses. Ultrastructural examination of the malignant peripheral nerve sheath tumor revealed cells with external lamina and interdigitation of cytoplasmic processes. Intracytoplasmic concentric lamellae were seen; they were regularly spaced with a periodicity of about 15 nm. Such structures, indistinguishable from myelin sheaths, have not been commonly associated with peripheral nerve sheath tumors in man. Electron microscopy and immunohistochemistry were useful in the diagnosis of these tumors as Schwannomas and in differentiation from other spindle cell tumors.

Dermal nerve sheath myxoma. A light and electron microscopic, histochemical and immunohistochemical study

Two cases of dermal nerve sheath myxoma have been examined by light and electron microscopy, and by immunohistochemical and histochemical methods. The nomenclature of this tumor has been debated, and the histogenesis unsettled. Light microscopically, the lobulated myxoid tumors were generally composed of spindle-shaped and stellate tumor cells in an abundant matrix of mucosubstances. Ultrastructural features indicated an origin from the peripheral nerve sheath; among the pertinent findings were a single or duplicated external lamina investing the cells, desmosome-like junctions, cytoplasmic microfilaments and myelin figures, and interdigitating cytoplasmic processes. S-100 protein was demonstrated by means of the immunoperoxidase technique within both tumors, further supporting this origin. The histochemical analysis of the mucosubstance showed the presence of sulphated glucosaminoglycans. The name dermal nerve sheath myxoma, suggested by Harkin and Reed, is recommended.

Chemistry and biology of the S-100 protein

The S-100 protein is specific for the nervous system and, being present in all vertebrates, shows a high degree of stability of structure during evolution. In adult animals it is primarily localized to glial elements, although there is some evidence that a small proportion may be present in neuronal nuclei or their plasma membranes. During development it is synthesized rapidly at a relatively late period of differentiation of the nervous system. In glioma cell cultures there is a control mechanism that seems to involve some kind of signal at the external surface of the plasma membrane, possibly specific cell-cell contact, to stimulate S-100 synthesis. All of these biological properties of S-100 suggest that it is connected with some specific essential function that is common to the nervous system of all vertebrates. Several chemical properties of S-100 provide clues to this function. It is an unusually acidic and soluble protein and, in the absence of Ca2+, has no detectable hydrophobic regions accessible to solvent. It is capable of specifically binding Ca2+, a process that causes S-100 to undergo a conformational change that exposes a hydrophobic region to the solvent and stimulates binding of S-100 to membranes. The conformational change and the membrane-binding properties are reversible when Ca2+ is removed and are antagonized by monovalent cations such as K+ and Na+. These chemical properties suggest that S-100 may, as part of its function in the nervous system, be bound to some hydrophobic site, possibly a membrane, and that the extent of this binding is regulated by concentrations of Ca2+, K+ and Na+. If this is true, then it is important, as the next step in working out its function, to discover the exact site where S-100 binds in the nervous system.

Effects of cyclic AMP on S-100 protein level in C-6 glioma cells

Dibutyryl cyclic AMP (dbcAMP) markedly elevated S-100 protein level in C-6 glioma cells in vitro. Quantitative analysis by two-dimensional polyacrylamide gel electrophoresis revealed that the elevation was caused by a combination of increased synthesis and reduced degradation of S-100 protein in C-6 cells exposed to dbcAMP. These results suggest that dbcAMP affects both the synthesis and the degradation of S-100 protein in C-6 cells.

S-100 protein in human glial tumours. Qualitative and quantitative studies

The authors studied a total of 48 human glial tumours for S-100 protein, an extremely acidic, protein specific to the nervous system, by immunohistochemistry and by micro-complement fixation assay in order to evaluate S-100 protein as an index for malignancy of glial tumours. All of 48 glial tumours analyzed in the present study demonstrated variable amounts of S-100 protein which might serve as a biochemical cell marker for glial tumours. The mean value of S-100 protein content in 3 ependymomas is higher than those of 19 low-grade (grades I, II) astrocytomas and 26 high-grade (grades III, IV) astrocytomas, being lowest in the latter. A statistically significant (P less than 0.001) difference in S-100 protein levels between low- and high-grade astrocytomas is observed, but not for ependymoma. At present, however, no correlation can be found between S-100 protein content of a tumor and the patient's survival time. Immunoperoxidase staining for S-100 protein in high-grade astrocytomas is generally weak in intensity and heterogeneous throughout the section, whereas that in low-grade astrocytomas and ependymomas is relatively strong and homogeneous, indicating that high-grade astrocytomas consist of a more heterogeneous population of tumour cells in terms of S-100 protein. These results show that the investigation of S-100 protein in a glial tumor is valuable to a certain extent in assessing the degree of differentiation or malignancy of the tumour.

S-100 protein in granular cell tumors (granular cell myoblastomas)

Outside the central nervous system S-100 is found only in Schwann cells and satellite cells of ganglia. It has also been demonstrated in Schwannomas and neurofibromas but is absent from soft tissue tumors of non-neural origin. S-100 protein was looked for in granular cell myoblastomas using an immunohistochemical technique in an attempt to further elucidate the histogenesis of these tumors. All tumor cells in the ten tumors studied were intensely stained with antiserum to S-100 including one with some malignant features. These results support the idea that granular cell myoblastomas arise from Schwann cells.

Distribution of S-100 protein outside the central nervous system

The distribution of S-100 outside the central nervous system in humans and rats was explored using antiserum to S-100 and the peroxidase anti-peroxidase method of Sternberger. In peripheral nerves the Schwann cells and the outermost part of the myelin sheaths were stained; axons were not. In dorsal root ganglia and ganglia of the autonomic nervous system only satellite cells were stained. In the adrenal medulla a considerable number of cells were stained. In all other organs studied Schwann cells and satellite cells of ganglia were the only elements that were stained. We conclude that S-100 could serve as a marker for Schwann cells in situ.

The S-100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system

The presence of the nervous system-specific S-100 antigen has been tested by microcomplement fixation assay with a monospecific anti-S-100 antiserum in cerebrospinal fluid (CSF) of subjects suffering from psychiatric disorders or various neurological diseases. The antigen was detectable in the CSF of most of the patients with neurological diseases characterized by an appreciable lesion in the nervous parenchyma, whereas it was generally absent from CSF of subjects presumably free from an extensive neurological lesion in the active phase. It is possible that the presence of S-100 IN CSF might be an index of active cell injury in the nervous parenchyma.

Glia-specific antigen in the intracranial tumors. Immunofluorescence study

26 gliomas and 14 non-glial tumors were examined for the presence of nervous system specific antigen (CGSA) to assess the antigenic properties of neoplastic tissue in relation to histogenesis and degree of differentiation of tumors. Double layer immunofluorescence (IMF) technique was used for the cellular localization of the antigen. CGSA was found in the cytoplasm of normal, reactive and neoplastic neuroglial cells. Well differentiated astrocytomas showed the strongest IMF reactions and largest number of IMF-positive cells. Tumors with histological signs of anaplasia displayed foci of IMF-negative cells irregularly distributed in the sections. There were no completely negative astrocytomas owing to a marked affinity of the specific astisera to the astrocytic cell line. In the oligodendrogliomas a smaller amount of the antigen was found than in the astrocytomas. Histological evidence of malignancy in these tumors was accompanied by strikingly small number of positive cells and weaker IMF reactions as compared to the well differentiated oligodendrogliomas. Anaplastic gliomas showed only traces of CGSA and non-glial tumors were entirely negative. The results suggest a deficiency of normal antigenic material in the neoplastic glia, particularly of oligodendrogliomas and anaplastic gliomas.